Advaxis (ADXS) Reaches New 52-Week High and Low at $1.60

Advaxis, Inc. (NASDAQ:ADXS) shares reached a new 52-week high and low on Monday . The company traded as low as $1.60 and last traded at $1.58, with a volume of 485844 shares trading hands. The stock had previously closed at $1.69.

A number of research analysts have weighed in on ADXS shares. HC Wainwright set a $23.00 price target on Advaxis and gave the company a “buy” rating in a research note on Wednesday, December 27th. Cantor Fitzgerald set a $19.00 price target on Advaxis and gave the company a “buy” rating in a research note on Thursday, December 28th. Finally, ValuEngine upgraded Advaxis from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

The company has a market cap of $88.41, a price-to-earnings ratio of -0.69 and a beta of 1.19.

Advaxis (NASDAQ:ADXS) last released its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.06. Advaxis had a negative return on equity of 149.14% and a negative net margin of 940.64%. The company had revenue of $2.06 million during the quarter, compared to analysts’ expectations of $3.03 million. equities research analysts predict that Advaxis, Inc. will post -1.73 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ADXS. Renaissance Technologies LLC acquired a new stake in shares of Advaxis in the fourth quarter valued at approximately $1,398,000. Deutsche Bank AG lifted its position in shares of Advaxis by 1,200.1% in the fourth quarter. Deutsche Bank AG now owns 467,324 shares of the biotechnology company’s stock valued at $1,326,000 after buying an additional 431,379 shares during the last quarter. Bank of Montreal Can lifted its position in shares of Advaxis by 16,465.9% in the fourth quarter. Bank of Montreal Can now owns 433,198 shares of the biotechnology company’s stock valued at $1,230,000 after buying an additional 430,583 shares during the last quarter. Franklin Street Advisors Inc. NC lifted its position in shares of Advaxis by 117.1% in the fourth quarter. Franklin Street Advisors Inc. NC now owns 129,800 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 70,000 shares during the last quarter. Finally, Capital Analysts LLC lifted its position in shares of Advaxis by 2,214.3% in the fourth quarter. Capital Analysts LLC now owns 69,428 shares of the biotechnology company’s stock valued at $3,962,000 after buying an additional 66,428 shares during the last quarter. 29.13% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Enterprise Leader and is the sole property of of Enterprise Leader. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://theenterpriseleader.com/2018/04/02/advaxis-adxs-reaches-new-52-week-high-and-low-at-1-60.html.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply